Company intelligence / Profile preview

Novel Biotechnology Inc.

Toronto, Ontario, Canadabusinesswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Novel Biotechnology has developed the NBx platform—a proprietary engineered microbial system that produces plasmid DNA with higher yield, faster growth rates, and improved quality compared to traditional E. coli systems. The company has demonstrated proof-of-concept with multiple complex constructs and is generating revenue through its services business. The commercial launch of the NBx platform occurred in late 2023; early access to the CyClone product begins May 2025.

Therapeutic areas: Other
Modalities: Plasmid DNANucleic acid-based therapeutics (enabling mRNA, gene therapy, cell therapy, nucleic acid vaccines)
Industry: Non-Drug Biotech

Partnerships

The company collaborates with leading biotech companies as customers/partners but no specific major pharmaceutical partnerships are named publicly as of June 2025Received support from the Ontario Center of Innovation

Beyond the preview

Go deeper on Novel Biotechnology Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel Biotechnology Inc..

Explore the full profile